Unlike IGF-1 LR3 , which is typically used systemically, IGF-1 DES is best used for: Targeted muscle growth Localized tissue repair Training-enhanced anabolism Heres how to use it effectively: Dosage Guidelines Typical IGF-1 DES dosing ranges from 20100 mcg per injection , depending on: Your experience level The size of the muscle group targeted Whether youre using it for growth or injury repair Dose-dependent stimulation of IGF-1 signaling pathways can be leveraged for site-specific hypertrophy or enhanced tissue regeneration. Philippou et al., Cell Communication and Signaling Injection Type and Technique Intramuscular (IM) injection directly into the target muscle Ideally injected pre-workout , ~1530 minutes prior to training that muscle group Rotate injection sites to avoid local irritation Example: If your goal is to bring up calves : Inject IGF-1 DES into medial and lateral gastrocnemius Perform calf training ~1530 min later to drive local blood flow and nutrient delivery Injection Timing Cycling Protocol IGF-1 DES should not be used continuously it is best cycled to: Prevent receptor downregulation Minimize risk of tissue overgrowth Typical cycles: 46 weeks on 24 weeks off For injury repair , shorter 24 week micro-cycles can be effective when stacked with: BPC-157 (BPC-157 for Recovery) TB500 (TB500) Stacking Potential IGF-1 DES is rarely used alone stacking it properly amplifies its effects: Stacking IGF-1 peptides with GH secretagogues and tissue repair peptides creates a synergistic environment for anabolism and regeneration. Musaro et al., Frontiers in Physiology Understood here is the next section, Potential Side Effects , written cleanly without summary clutter: Potential Side Effects Like any powerful growth factor , IGF-1 DES must be used intelligently to avoid unwanted effects
There's no single correct approach, so experiment to find what fits your routine
Hence, changes in intra-portal insulin levels need to be taken into consideration to correctly interpret the alterations in the GH/IGF-I axis in healthy and disease states as this helps the clinician in formulating the decision-making process of when and how to perform appropriate diagnostic work-up and whether to offer treatment to improve any accompanying metabolic consequences
White, A., et al., Reduced glucose-stimulated insulin secretion following a 1-wk IGF-1 infusion in late gestation fetal sheep is due to an intrinsic islet defect
